Form 6-K TAKEDA PHARMACEUTICAL For: Jul 05
- Wall Street closes little changed on Fed policy fears
- NVIDIA (NVDA) Stock Tumbles After Weak Q2 Preliminary Results on Gaming Weakness
- JPMorgan, Morgan Stanley and Citi Discuss Outlook for US Stocks
- Vista Equity Partners to Take Avalara (AVLR) Private in an $8.4 Billion Deal
- Palantir (PLTR) Stock Tumbles 15% on Soft Outlook, Citi Sees Many Negatives
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of July 2022
Commission File Number: 001-38757
TAKEDA PHARMACEUTICAL COMPANY LIMITED
(Translation of registrant’s name into English)
1-1, Nihonbashi-Honcho 2-Chome
Chuo-ku, Tokyo 103-8668
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Information furnished on this form:
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|TAKEDA PHARMACEUTICAL COMPANY LIMITED|
|Date: July 5, 2022||By:||/s/ Norimasa Takeda|
Chief Accounting Officer and Corporate Controller
Results of the Exercise of Voting Rights of the 146th Ordinary General Meeting of Shareholders
1.Reason for the submission
The report is submitted pursuant to the provisions of Article 24-5, Paragraph 4 in the Financial Instruments and Exchange Act, and Article 19, Paragraph 2, Item 9-2 in the Cabinet Office Ordinance on Disclosure of Corporate Information, etc., which shows the results of the resolution on the matters to be resolved at the 146th Ordinary General Meeting of Shareholders of the Company held on June 29, 2022.
 The date of the shareholders meeting
June 29, 2022
 Details of matters to be resolved
First Proposal: Appropriation of Surplus
Concerning the year-end dividend
90 yen per share of common stock of the Company
Second Proposal: Partial Amendment to the Articles of Incorporation
To partially amend the Articles of Incorporation in order to accommodate a system for electronic provision of materials for general meeting of shareholders in line with the amended provisions stipulated in the proviso to Article 1 of the Supplementary Provisions of the Act Partially Amending the Companies Act (Act No. 70 of 2019) which will be enforced on September 1, 2022.
Third Proposal: Election of Eleven (11) Directors who are not Audit and Supervisory Committee Members
To elect Christophe Weber, Masato Iwasaki, Andrew Plump, Costa Saroukos, Olivier Bohuon, Jean-Luc Butel, Ian Clark, Steven Gillis, Masami Iijima, John Maraganore and Michel Orsinger as Directors who are not Audit and Supervisory Committee Members.
Fourth Proposal: Election of Four (4) Directors who are Audit and Supervisory Committee Members
To elect Koji Hatsukawa, Emiko Higashi, Yoshiaki Fujimori and Kimberly A. Reed as Directors who are Audit and Supervisory Committee Members.
Fifth Proposal: Payment of Bonuses to Directors who are not Audit and Supervisory Committee Members
To pay bonuses within a total of 500 million yen to the 3 Directors who are not Audit and Supervisory Committee Members (excluding Directors resident overseas and External Directors) in office as of the end of this fiscal year.
 Numbers of voting rights for approval of, against and abstaining from each of the matters to be resolved, requirements for each of the matters to be resolved to be approved and the results for each resolution
|Matter to be resolved||Approval (No. of voting rights)||Against (No. of voting rights)||Abstention (No. of voting rights)||Total No. of voting rights exercised|
(Proportion of approval)
|11,519,996||Approval (99.19%)||(Note) 1|
|Fourth Proposal||(Note) 3|
Kimberly A. Reed
|Approval (98.02%)||(Note) 1|
(Note) 1. Approval requires a majority of the voting rights of shareholders in attendance and able to exercise voting rights.
2. Approval requires the attendance of shareholders possessing at least one third of the voting rights of shareholders who are able to exercise voting rights and two thirds of the voting rights of shareholders in attendance.
3. Approval requires the attendance of shareholders possessing at least one third of the voting rights of shareholders who are able to exercise voting rights and a majority of the voting rights of shareholders in attendance.
 Reason for not adding some of the voting rights of shareholders who attended the Ordinary General Meeting of Shareholders to the number of voting rights for approval of, against or abstaining from each of the matters to be resolved
The requirements for approval of the resolutions were met by the advance voting by the day prior to the date of this Ordinary General Meeting of Shareholders and the tallying of votes received from some of the shareholders who attended on the day of the meeting for which the approval or otherwise of the resolutions could be confirmed, and the resolutions were thus passed legally in accordance with the Companies Act. Therefore, the remaining votes of shareholders who attended on the day of this Ordinary General Meeting of Shareholders were not added to the number of voting rights for approval of, against or abstaining from each of the matters to be resolved.
End of Document
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Takeda Pharmaceutical (4502:JP) (TAK) PT Raised to JPY6,200 at Citi
- Ashland completes sale of land located in Ajax, Canada to Sunray Group of Hotels Inc, for CAD $12.25 million
- Ainos Announces Pricing of $3.3 Million Public Offering, Uplisting to NASDAQ, and Reverse Stock Split
Create E-mail Alert Related CategoriesSEC Filings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!